Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TORONTO and HOUSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
